Umbilical Cord Blood Banking Market is Segmented By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), By Application (Bone marrow failure Syndrome, Leukaemia, Metabolic disorder, Lymphoma, Others), By Storage Option (Public UCB banks, Private UCB banks), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Report Overview
The Umbilical Cord Blood Banking Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Umbilical cord blood banking involves the collection and storage of cord blood stem cells for potential medical use. The market is driven by the growing awareness of the therapeutic potential of cord blood stem cells and the increasing number of cord blood banks worldwide. In the Europe region, the Umbilical Cord Blood Banking Market is experiencing rapid growth. Key players in the market include Company X, Company Y, Company Z, and other prominent players.
The procedure of collecting cord blood, removing and cryogenically freezing its stem cells and other immune system cells for future medical use is known as cord blood banking.
As per DataM Intelligence, Umbilical Cord Blood Banking Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Umbilical Cord Blood Banking Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Umbilical Cord Blood Banking Market in the United States and Canada produces the utmost share. Whereas the European Umbilical Cord Blood Banking Market is projected to continue its presence globally during the period of 2023- 2030.
Umbilical Cord Blood Banking Market Scope and Summary
| Metrics | Details |
| Market CAGR | High |
| Segments Covered | By Service Type, By Application, By Storage Option, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more insights - Download the Sample
Umbilical Cord Blood Banking Market Dynamics and Trends
The increasing use of umbilical cord blood and the rise in the incidence of blood cancer are expected to drive the growth of the umbilical cord blood banking market.
Increasing use of umbilical cord blood is driving the growth of the umbilical cord blood banking market
Cord blood stem cells have been employed in transplant therapy and can now help treat approximately 80 diseases. Cord blood stem cells are used in transplants to help rebuild healthy blood and immune systems destroyed by the disease. Cord blood has been used in clinical research trials for previously considered incurable disorders, such as autism and brain damage. In the last few years, cord blood stem cells have been expanding beyond transplant medicine into fields of regenerative medicine. Cord blood is used in regenerative medicine in a different way than it is in transplant medicine. Rather than developing new blood and immune system as in transplants, cord blood is used instead.
There are various advantages of employing umbilical cord blood stem cells for transplantation. The first benefit is that collecting and processing umbilical cord blood is relatively simple. Cord blood, which was once thought to be a waste product after birth, may now be easily stored. The cord blood is soon available for use after it is stored and delivered to a storage facility. They also provide decreased risk of disease transmission.
The rise in the incidence of blood cancer is estimated to drive the umbilical cord blood banking market
Leukemia, lymphoma, myeloma and myelodysplastic syndromes (MDS) are types of cancer that can affect the bone marrow, the blood cells, the lymph nodes and other parts of the lymphatic system. According to Leukemia & Lymphoma Society, in 2021, around 61,090 people are expected to be diagnosed with leukemia. Approximately 23,660 deaths (13,900 males and 9,760 females) in the US will be attributed to leukemia in 2021. Every year, an estimated 300,000 new cases of leukaemia are diagnosed worldwide (2.8 per cent of all new cancer cases). CLL is the most common kind of leukaemia in Western countries, accounting for 25% of cases, CML for 20% of cases, and AML for 20% of cases.
Umbillical cord blood is approved for use only in hematopoietic stem cell transplantation procedures performed on patients with hematopoietic (blood-forming) system abnormalities. Umbillical cord blood contains blood-forming stem cells that can be utilized to treat blood malignancies like leukaemia and lymphoma and blood and immune system illnesses like sickle cell disease and Wiskott-Aldrich syndrome. Very high-dose chemotherapy or radiation therapy used to treat cancer may cause significant damage to blood-forming cells in the marrow, the spongy material inside the centre of bones. Radiation therapy or high-dose chemotherapy followed by stem cell transplantation may assist certain patients with leukaemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or other blood malignancies. Other hereditary or acquired marrow or immune system illnesses may benefit from stem cell transplantation as well. After the chemotherapy transplanted stem cells from cord blood can help regrow the healthy blood cells. Hence, it is estimated to drive the market in the forecast period.
Disadvantages associated with umbilical cord blood banking is estimated to hamper the market growth
Despite the advantages of employing umbilical cord blood stem cells for transplantation, there are certain drawbacks. Engraftment must be seen for stem cell transplants to be successful. The opposite of rejection, engraftment suggests that the stem cell transplant is "working." The recovery of neutrophil (a type of white blood cell) and platelet (a clotting factor) production are two detectable markers of engraftment. Umbilical cord blood cell transplants take longer than bone marrow stem cell transplants to show these two clinical recovery indicators. To put it another way, the lab numbers for white blood cell and platelet production take longer to arrive. Umbilical cord blood cell transplants take longer than bone marrow stem cell transplants to show these two clinical recovery indicators. In other words, after umbilical cord blood stem cell transplants, lab values for white blood cell and platelet production take longer to increase than after bone marrow stem cell transplants.
Cell dosage is one of the parameters that influence engraftment time. The volume of blood collected from the umbilical cord is proportional to the cell dose. The amount of useful stem cells in a blood sample is referred to as cell dosage. The quantity of stem cells recovered from cord blood is roughly 10% less than that obtained from bone marrow due to the low volume of cells harvested. In most cases, a single unit of umbilical cord blood includes 50 to 200 mL of blood. In around half of all cord blood collections or more, insufficient amounts of cord blood are collected. In general, fewer stem cells are required for cord blood transplantation, and a volume of 50 to 100 ml of cord blood is usually sufficient for a kid or small adult's cell dose. However, because the cord blood volume is restricted, it is impossible to collect extra stem cells from the newborn if the recipient requires them. Umbilical cord blood banking is subject to a substantial lack of regulation. The lack of quality control has an impact on the quality of the transplantable specimen. Some cord blood banks have applied for voluntary accreditation. Also, the process differs depending on whether the bank is public or private.
COVID-19 Impact on Umbilical Cord Blood Banking Market Growth
COVID-19 has affected the healthcare industry. To stop its development, government-imposed lockdown. During covid, the increased value of the market was credited to efforts of cell therapy to treat COVID-19 and over half of those COVID-19 trials requires umbilical cord MSC. Hence, the pandemic created a new market for the companies that manufacture MSC products from birth tissues donated. Many of these companies applied for COVID-19 Emergency Use Authorizations from the FDA and partner with local Public UCB banks to treat COVID-19 patients. Hence, the umbilical cord blood banking market has seen a positive impact.
Umbilical Cord Blood Banking Market Segment and Shares
Based on service type, sample preservation and storage segment is dominating the umbilical cord blood banking market
Storing umbilical cord blood in public banks should be done by family. However, pregnant families consider private cord blood storage if they have a relative with a condition known that can be treated with stem cell transplants. Two types of banks have emerged to collect and store umbilical cord blood: 1) public banks and 2) private banks. Found in the umbilical cord and the placenta's blood vessels. Cord blood is collected after the umbilical cord of a baby is cut. As the umbilical cord blood is collected typically after the baby is delivered and the cord is cut, the procedure is safe for the mother and baby.
Cord blood is frozen after collection and can be securely preserved for many years. The freezing procedure, known as cryopreservation, is critical for maintaining the integrity of the cells. Cord blood must be stored with caution. Alternatively, some give their cord blood to a public bank so that doctors can utilise it to help a patient who requires a hematopoietic stem cell transplant. Depending on the source, level of processing, and intended use, the FDA controls cord blood in various ways. Cord blood kept for use by a patient not related to the donor fulfils the legal definitions of both a medication and a biological product. Before being used, cord blood in this category must meet additional criteria and be licensed under a biologics licence application or an experimental new medication application. The FDA's standards help to guarantee that these goods are safe and effective in their intended applications. Cord blood collection is less difficult, painful, and harmful for the donor than bone marrow collection. The newborn or the person giving birth is not in danger from cord blood collection. Cord blood banks can freeze and preserve cord blood, making it available whenever needed. Hence, this segment is assumed to dominate the market due to the ease of collection and increased demand for its preservation.
The bone marrow failure syndrome segment is dominating the umbilical cord blood banking market
The treatment milestones for idiopathic and hereditary bone marrow failure (BMF) illnesses are hematopoietic stem cell transplantation (HSCT) and immunosuppressive medication (IST). In the absence of an appropriate donor, cord blood transplantation (CBT) has expanded the potential of HSCT for many patients, while this technique has been less common in recent years in various haematological illnesses, it remains an option for patients with BMF syndromes. Nonetheless, the conditioning regimen and cord blood unit selection should be optimised to lower the risk of graft failure and transplant-related mortality. Bone marrow failure (BMF) disorders are rare diseases that can occur in children and adults due to idiopathic or inherited disorders.
Transplant of bone marrow is the best hope for a cure and life, while umbilical cord blood can provide the replacement tissue needed for the transplant. This is known as a cord blood transfusion when it is used. More than 25,000 umbilical cord blood transplantation have been done around the world. For bone marrow transplantation, doctors have experience using stem cells from umbilical cord blood (cord blood transplant), peripheral blood (peripheral blood stem cell transplant) and bone marrow (bone marrow transplant).
Based on storage options, public UCB banks accounted for the largest market share in the umbilical cord blood banking market
Public umbilical cord blood banks accept altruistic cord blood donations without charging a fee. Donated units are additionally processed, antigen typed and frozen so that they can be used right away. Unlike private banks, public banks do not hold units in trust for the family who donated them; instead, they are open to the whole public. A family that donates blood is no more likely than anyone else in the general community to receive the blood. The public cord blood banks work similarly to venous blood banks. The blood is provided on an "as-needed" basis, with a processing fee applied to help recuperate some of the storage costs. Locating a public bank may require less legwork than finding a private one. Delivering in a hospital that works directly with the National Marrow Donor Program's public cord blood banks network is the simplest way to donate openly. Public cord blood banks pay for everything, including the collection, testing, and storing of umbilical cord blood. Worldwide over 400,000 units in more than 100 quality controlled public cord blood banks are available. Cord blood units are held in public banks and are available to patients in need worldwide. If they are HLA-matched, a patient from anywhere globally can access cord blood units in a public bank through a search conducted by several registries across the world.
Umbilical Cord Blood Banking Market Geographical Analysis
North America region is expected to dominate the umbilical cord blood banking market
North America umbilical cord blood banking market is expected to dominate with the increasing prevalence of blood disorders and increased use of umbilical cord blood banking in this region. For instance, in the US, an estimated combined total of 186,400 people are expected to be diagnosed with leukemia, lymphoma or myeloma in 2021. An estimated 1,519,907 people in the United States (US) are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs). Umbilical cord blood has a growing and important role in the treatment of leukemia, lymphoma, sickle cell anemia and other life-threatening diseases. Hence, with the increasing prevalence of leukemia in North America, the demand for umbilical cord blood is estimated to drive the market.
The community's health is aided by public cord blood banking. Public banks collect qualified cord blood donations from healthy pregnancies and store them in case one of them matches a patient in need of a stem cell transplant. “Be The Match” is the name of the donor registry in the United States. Cord blood transplants are more likely to occur in patients with a rare genetic type. Parents must deliver their baby to a hospital that allows cord blood donations to donate cord blood to a public bank. Public cord blood banking is strongly advocated by both the American Medical Association (AMA) and the American Academy of Pediatrics.
Umbilical Cord Blood Banking Companies and Competitive Landscape
Some of the major key players in the umbilical cord blood banking market are China Cord Blood Corporation, Cord Blood America, Inc., CBR Systems, Inc., Cordlife Group Limited, Cryo-Cell International, Inc., Cryo-Save AG, Lifeforce Cryobanks, National Cord Blood Program, ViaCord, Inc., Virgin Health Bank, CordVida, Americord, CryoHoldco, and Vita34.
Cord Blood America, Inc.
Overview: Cord Blood America, Inc. (CBAI) is in the business of collecting, testing, processing, and conserving umbilical cord blood through its wholly-owned subsidiary CorCell Companies, Inc. Allowing families to save cord blood at the time of birth of a child for future stem cell therapy.
Product Portfolio: The company comprises cord blood stem cell collection, cryo-preservation and collection services for the placenta, cord blood and whole umbilical cords.
Key Development: California Cryobank Stem Cell Services LLC ("FamilyCord") acquired the asset of Cord Blood America Inc. ("CBAI") uniting two of the industry's most respected stem cell companies. FamilyCord will maintain the long-term cryogenic storage of the stem cell units in its state-of-the-art biorepository.
